Université Paris Cité, Centre de Recherche sur l'Inflammation , INSERM U1149, CNRS ERL8252 , Paris , France.
Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepatology , Hôpital Beaujon , Clichy , France.
Hepatology. 2023 Apr 1;77(4):1348-1365. doi: 10.1002/hep.32731. Epub 2022 Sep 16.
Hepatitis B virus (HBV) infection causes oxidative stress (OS) and alters mitochondria in experimental models. Our goal was to investigate whether HBV might alter liver mitochondria also in humans, and the resulting mitochondrial stress might account for the progression of fibrosis in chronic hepatitis B (CHB).
The study included 146 treatment-naïve CHB mono-infected patients. Patients with CHB and advanced fibrosis (AF) or cirrhosis (F3-F4) were compared to patients with no/mild-moderate fibrosis (F0-F2). Patients with CHB were further compared to patients with chronic hepatitis C (CHC; n = 33), nonalcoholic steatohepatatis (NASH; n = 12), and healthy controls ( n = 24). We detected oxidative damage to mitochondrial DNA (mtDNA), including mtDNA strand beaks, and identified multiple mtDNA deletions in patients with F3-F4 as compared to patients with F0-F2. Alterations in mitochondrial function, mitochondrial unfolded protein response, biogenesis, mitophagy, and liver inflammation were observed in patients with AF or cirrhosis associated with CHB, CHC, and NASH. In vitro , significant increases of the mitochondrial formation of superoxide and peroxynitrite as well as mtDNA damage, nitration of the mitochondrial respiratory chain complexes, and impairment of complex I occurred in HepG2 cells replicating HBV or transiently expressing hepatitits B virus X protein. mtDNA damage and complex I impairment were prevented with the superoxide-scavenging Mito-Tempo or with inducible nitric oxide synthase (iNOS)-specific inhibitor 1400 W.
Our results emphasized the importance of mitochondrial OS, mtDNA damage, and associated alterations in mitochondrial function and dynamics in AF or cirrhosis in CHB and NASH. Mitochondria might be a target in drug development to stop fibrosis progression.
乙型肝炎病毒(HBV)感染会导致氧化应激(OS),并改变实验模型中的线粒体。我们的目标是研究 HBV 是否也会改变人类的肝线粒体,以及由此产生的线粒体应激是否可能导致慢性乙型肝炎(CHB)纤维化的进展。
该研究纳入了 146 例未经治疗的 CHB 单感染患者。将 CHB 伴晚期纤维化(AF)或肝硬化(F3-F4)患者与无/轻度-中度纤维化(F0-F2)患者进行比较。CHB 患者进一步与慢性丙型肝炎(CHC;n=33)、非酒精性脂肪性肝炎(NASH;n=12)和健康对照(n=24)进行比较。我们检测到线粒体 DNA(mtDNA)的氧化损伤,包括 mtDNA 链断裂,并在 F3-F4 患者中发现了多种 mtDNA 缺失,与 F0-F2 患者相比。在与 CHB、CHC 和 NASH 相关的 AF 或肝硬化患者中观察到线粒体功能、未折叠蛋白反应、生物发生、线粒体自噬和肝炎症的改变。在体外,复制 HBV 或瞬时表达乙型肝炎病毒 X 蛋白的 HepG2 细胞中线粒体超氧化物和过氧亚硝酸盐的形成以及 mtDNA 损伤、线粒体呼吸链复合物的硝化和复合物 I 的损伤显著增加。超氧化物清除剂 Mito-Tempo 或诱导型一氧化氮合酶(iNOS)特异性抑制剂 1400W 可预防 mtDNA 损伤和复合物 I 损伤。
我们的研究结果强调了线粒体 OS、mtDNA 损伤以及相关的线粒体功能和动力学改变在 CHB 和 NASH 中 AF 或肝硬化中的重要性。线粒体可能是阻止纤维化进展的药物开发的靶点。